Tirbanibulin Levels and Effects while Breastfeeding
Summary of Use during Lactation
Topical tirbanibulin has not been studied during breastfeeding.
However, after topical administration, serum concentrations are very low and the drug is 88% bound to plasma proteins, so amounts in milk are likely to be very low. If tirbanibulin is required by the mother, it is not a reason to discontinue breastfeeding. Do not apply tirbanibulin to the breast or nipple and ensure that the infant's skin does not come into direct contact with the areas of skin that have been treated.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Tirbanibulin
CAS Registry Number
897016-82-9
Drug Class
Breast Feeding
Lactation
Antineoplastic Agents
Dermatologic Agents
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.